Select Medical (NYSE:SEM) Issues FY 2025 Earnings Guidance

Select Medical (NYSE:SEM) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.090-1.190 for the period, compared to the consensus EPS estimate of 1.430. The company issued revenue guidance of $5.4 billion-$5.6 billion, compared to the consensus revenue estimate of $5.8 billion.

Select Medical Trading Down 0.8 %

NYSE SEM opened at $19.11 on Friday. Select Medical has a one year low of $18.02 and a one year high of $40.98. The company’s 50 day moving average price is $19.13 and its 200 day moving average price is $28.07. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.13 and a current ratio of 1.13. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of 8.93, a PEG ratio of 0.64 and a beta of 1.45.

Select Medical (NYSE:SEM) last posted its quarterly earnings results on Thursday, February 20th. The health services provider reported $0.18 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.11). Select Medical had a net margin of 3.97% and a return on equity of 15.99%. On average, sell-side analysts predict that Select Medical will post 1.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on SEM shares. Benchmark lowered shares of Select Medical from a “buy” rating to a “hold” rating in a research note on Monday, November 25th. UBS Group dropped their price objective on shares of Select Medical from $40.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, January 3rd. Royal Bank of Canada lifted their price objective on shares of Select Medical from $40.00 to $47.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Finally, StockNews.com raised shares of Select Medical from a “hold” rating to a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.50.

Insider Transactions at Select Medical

In other Select Medical news, Director Marilyn B. Tavenner sold 32,000 shares of Select Medical stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $21.09, for a total value of $674,880.00. Following the completion of the transaction, the director now owns 22,000 shares of the company’s stock, valued at $463,980. The trade was a 59.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Robert G. Breighner, Jr. sold 4,989 shares of Select Medical stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $19.95, for a total transaction of $99,530.55. Following the completion of the transaction, the vice president now directly owns 30,356 shares of the company’s stock, valued at approximately $605,602.20. This represents a 14.12 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 19.14% of the company’s stock.

About Select Medical

Select Medical Holdings Corporation, through its subsidiaries, operates critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. It operates in four segments: Critical Illness Recovery Hospital, Rehabilitation Hospital, Outpatient Rehabilitation, and Concentra.